ABVC - ABVC Biopharma Inc
NYSE * Healthcare * Biotechnology
$1.30
$-0.14 (-9.72%)
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Price Chart
ABVC Key Statistics
Market Cap
$34.06M
P/B Ratio
3.31
EPS
$-0.39
Revenue Growth
+1.0%
Employees
16
How ABVC Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
#1
of 6
Size Rank
#6
of 6
ABVC Biopharma Inc Company Information
- Headquarters
- 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538, undefined
- Website
- www.abvcpharma.com
- Sector
- Healthcare
- Industry
- Biotechnology